HomeCompareCMAX vs ABBV

CMAX vs ABBV: Dividend Comparison 2026

CMAX yields 474.50% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CMAX wins by $41056.45M in total portfolio value
10 years
CMAX
CMAX
● Live price
474.50%
Share price
$0.42
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41056.55M
Annual income
$29,023,903,231.72
Full CMAX calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CMAX vs ABBV

📍 CMAX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCMAXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CMAX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CMAX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMAX
Annual income on $10K today (after 15% tax)
$40,332.15/yr
After 10yr DRIP, annual income (after tax)
$24,670,317,746.96/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, CMAX beats the other by $24,670,295,880.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMAX + ABBV for your $10,000?

CMAX: 50%ABBV: 50%
100% ABBV50/50100% CMAX
Portfolio after 10yr
$20528.33M
Annual income
$14,511,964,478.72/yr
Blended yield
70.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CMAX
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Price Target
$2.60
+516.8% upside vs current
Range: $2.20 — $3.00
Altman Z
-7.4
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMAX buys
0
ABBV buys
0
No recent congressional trades found for CMAX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCMAXABBV
Forward yield474.50%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$41056.55M$104.7K
Annual income after 10y$29,023,903,231.72$25,725.73
Total dividends collected$39997.38M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$2.60$256.15

Year-by-year: CMAX vs ABBV ($10,000, DRIP)

YearCMAX PortfolioCMAX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$58,150$47,449.58$11,559$438.51+$46.6KCMAX
2$320,087$257,866.70$13,494$640.86+$306.6KCMAX
3$1,669,070$1,326,577.30$15,951$945.97+$1.65MCMAX
4$8,250,714$6,464,808.54$19,152$1,413.89+$8.23MCMAX
5$38,695,072$29,866,808.47$23,443$2,146.38+$38.67MCMAX
6$172,312,631$130,908,904.14$29,391$3,321.96+$172.28MCMAX
7$729,186,766$544,812,250.78$37,948$5,265.87+$729.15MCMAX
8$2,934,919,616$2,154,689,776.51$50,795$8,596.74+$2934.87MCMAX
9$11,245,464,525$8,105,100,535.41$71,034$14,549.41+$11245.39MCMAX
10$41,056,550,273$29,023,903,231.72$104,715$25,725.73+$41056.45MCMAX

CMAX vs ABBV: Complete Analysis 2026

CMAXStock

CareMax, Inc. provides medical services through physicians and health care professionals. It offers a suite of health care and social services to its patients, including primary care, specialty care, telemedicine, health and wellness, optometry, dental, pharmacy, and transportation. The company also provides CareOptimize, a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians in the United States. As of December 31, 2021, it operated 48 multi-specialty medical care centers in Florida, Tennessee, and New York. The company is headquartered in Miami, Florida.

Full CMAX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CMAX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMAX vs SCHDCMAX vs JEPICMAX vs OCMAX vs KOCMAX vs MAINCMAX vs JNJCMAX vs MRKCMAX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.